​Pharmacology - Rosiglitazone

​Pharmacology - Rosiglitazone 
Rosiglitazone action reduces the amount of glucose that is present in the blood.

Method of Operation 
It does this by activating the peroxisomal proliferator, also known as the active receptor, in skeletal muscle, liver, and adipose tissue. This triggers the transcription of genes that code for proteins that play a crucial role in insulin action.
The reduction of glucose release from the liver, the increase in glucose absorption into muscle, and the increase in sensitivity (lower resistance) to insulin are all significant effects in the prevention and management of blood glucose levels. Over the course of two to three months, the effects build.

Easily absorbed through the mouth, with a strong affinity for plasma proteins. Predominantly eliminated through the P450 metabolism in the liver. There is a possibility of interactions with medications that either inhibit or induce cytochrome P450. There is some action of metabolites, but the half-life is only seven hours.

Use in Clinical Settings 
There is diabetes mellitus type 2. Usually administered in conjunction with a sulphonylurea or metformin.

Adverse Effects 
Accumulation of weight and retention of fluids (may lead to heart failure). A minor risk of hypoglycemia is present. Glitazones are a group of medications that should be avoided by people who have liver illness since some of them are hepatotoxic.